Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ALNYLAM PHARMACEUTICALS, INC.ALNY · Entity 3132 | EVP Chief R&D | March 04, 2026 | March 06, 2026 |
| SQZ Biotechnologies CoSQZ · Entity 112267 | Director | June 14, 2023 | June 15, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ALNYLAM PHARMACEUTICALS, INC.
Report date March 04, 2026 · Filed March 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 18,693 |
Ending reported balance
After 2026-03-05 transaction · row 12
12 source rows · reconciled sequenceRow 1 · 2026-03-04 · Sale · Disposed 106 · Balance 23,300 F1: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations upon the vesting of restricted stock units. F2: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $318.27 to $319.27. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Row 2 · 2026-03-04 · Sale · Disposed 102 · Balance 23,198 F1: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations upon the vesting of restricted stock units. F3: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $319.28 to $320.28. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Row 3 · 2026-03-04 · Sale · Disposed 215 · Balance 22,983 F1: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations upon the vesting of restricted stock units. F4: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $320.33 to $321.33. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Row 4 · 2026-03-04 · Sale · Disposed 289 · Balance 22,694 F1: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations upon the vesting of restricted stock units. F5: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $321.34 to $322.31. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Row 5 · 2026-03-04 · Sale · Disposed 350 · Balance 22,344 F1: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations upon the vesting of restricted stock units. F6: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $322.36 to $323.36. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Row 6 · 2026-03-04 · Sale · Disposed 767 · Balance 21,577 F1: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations upon the vesting of restricted stock units. F7: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $323.38 to $324.35. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Row 7 · 2026-03-04 · Sale · Disposed 272 · Balance 21,305 F1: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations upon the vesting of restricted stock units. F8: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $324.39 to $325.38. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Row 8 · 2026-03-04 · Sale · Disposed 208 · Balance 21,097 F1: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations upon the vesting of restricted stock units. F9: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $325.40 to $326.21. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Row 9 · 2026-03-05 · Sale · Disposed 654 · Balance 20,443 F10: This transaction was made pursuant to a Rule 10b5-1(c) trading plan adopted by the Reporting Person on November 20, 2025. F11: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $322.03 to $322.96. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Row 10 · 2026-03-05 · Sale · Disposed 740 · Balance 19,703 F10: This transaction was made pursuant to a Rule 10b5-1(c) trading plan adopted by the Reporting Person on November 20, 2025. F12: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $323.09 to $324.08. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Row 11 · 2026-03-05 · Sale · Disposed 510 · Balance 19,193 F10: This transaction was made pursuant to a Rule 10b5-1(c) trading plan adopted by the Reporting Person on November 20, 2025. F13: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $324.26 to $325.20. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Row 12 · 2026-03-05 · Sale · Disposed 500 · Balance 18,693 F10: This transaction was made pursuant to a Rule 10b5-1(c) trading plan adopted by the Reporting Person on November 20, 2025. F14: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $325.67 to $326.40. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. |
| Common StockSEC Table I · non-derivative | Indirectby Managed Account | 431 |
Reported balance
Holding disclosure · report date 2026-03-04 · row 13
Holding and transaction disclosures are not merged.
1 source rowRow 13 · Balance 431 F15: Reflects shares of ALNY common stock acquired by the Reporting Person under the issuer 401(k) plan as a result of the issuer 401(k) matching contribution program. |
| Common StockSEC Table I · non-derivative | Indirectby Trust | 250 |
Reported balance
Holding disclosure · report date 2026-03-04 · row 14
Holding and transaction disclosures are not merged.
1 source rowRow 14 · Balance 250 F16: Represents shares held in trust, of which the Reporting Persons spouse is co-trustee. The Reporting Person disclaims beneficial ownership of these shares, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations upon the vesting of restricted stock units.
F2: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $318.27 to $319.27. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F3: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $319.28 to $320.28. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F4: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $320.33 to $321.33. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F5: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $321.34 to $322.31. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F6: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $322.36 to $323.36. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F7: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $323.38 to $324.35. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F8: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $324.39 to $325.38. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F9: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $325.40 to $326.21. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F10: This transaction was made pursuant to a Rule 10b5-1(c) trading plan adopted by the Reporting Person on November 20, 2025.
F11: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $322.03 to $322.96. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F12: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $323.09 to $324.08. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F13: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $324.26 to $325.20. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F14: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $325.67 to $326.40. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F15: Reflects shares of ALNY common stock acquired by the Reporting Person under the issuer 401(k) plan as a result of the issuer 401(k) matching contribution program.
F16: Represents shares held in trust, of which the Reporting Persons spouse is co-trustee. The Reporting Person disclaims beneficial ownership of these shares, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
SQZ Biotechnologies Co
Report date June 14, 2023 · Filed June 15, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $0.54 · Expires 2033-06-13 | Direct | 39,875 |
Reported balance
After 2023-06-14 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-06-14 · Grant · Acquired 39,875 · Balance 39,875 F1: The option vests and become exercisable on the earlier of (i) June 14, 2024 or (ii) the day immediately prior to the date of the next annual meeting of stockholders following the date of grant, in each case subject to the recipient's continued service on the Board at such time. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests and become exercisable on the earlier of (i) June 14, 2024 or (ii) the day immediately prior to the date of the next annual meeting of stockholders following the date of grant, in each case subject to the recipient's continued service on the Board at such time.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 28, 2023 Filed Apr 28, 2023 21:54 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 955 | $200.35 | $191,334.25 |
DisclosureSEC source: 0001735276-23-000044 · edgardoc.xml · nonDerivative · entry 11 Garg Pushkal · CIK 0001829252 · CMO & EVP Dev & Med Affairs 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,438 F7 · kind: These sales were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 16, 2022. F12 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $ 199.90 to $200.82. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| April 28, 2023 Filed Apr 28, 2023 21:54 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 385 | $199.54 | $76,822.90 |
DisclosureSEC source: 0001735276-23-000044 · edgardoc.xml · nonDerivative · entry 10 Garg Pushkal · CIK 0001829252 · CMO & EVP Dev & Med Affairs 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,393 F7 · kind: These sales were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 16, 2022. F11 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $ 198.89 to $199.89. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| April 28, 2023 Filed Apr 28, 2023 21:54 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 715 | $198.03 | $141,591.45 |
DisclosureSEC source: 0001735276-23-000044 · edgardoc.xml · nonDerivative · entry 9 Garg Pushkal · CIK 0001829252 · CMO & EVP Dev & Med Affairs 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,778 F7 · kind: These sales were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 16, 2022. F10 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $ 197.57 to $198.32. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| April 28, 2023 Filed Apr 28, 2023 21:54 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 103 | $196.62 | $20,251.86 |
DisclosureSEC source: 0001735276-23-000044 · edgardoc.xml · nonDerivative · entry 8 Garg Pushkal · CIK 0001829252 · CMO & EVP Dev & Med Affairs 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,493 F7 · kind: These sales were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 16, 2022. F9 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $ 196.31 to $196.66. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| April 28, 2023 Filed Apr 28, 2023 21:54 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 204 | $195.46 | $39,873.84 |
DisclosureSEC source: 0001735276-23-000044 · edgardoc.xml · nonDerivative · entry 7 Garg Pushkal · CIK 0001829252 · CMO & EVP Dev & Med Affairs 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,596 F7 · kind: These sales were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 16, 2022. F8 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $ 194.80 to $195.61. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| April 27, 2023 Filed Apr 28, 2023 21:54 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 129 | $197.08 | $25,423.32 |
DisclosureSEC source: 0001735276-23-000044 · edgardoc.xml · nonDerivative · entry 6 Garg Pushkal · CIK 0001829252 · CMO & EVP Dev & Med Affairs 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,800 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form. Read SEC document |
| April 27, 2023 Filed Apr 28, 2023 21:54 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 80 | $195.65 | $15,652.00 |
DisclosureSEC source: 0001735276-23-000044 · edgardoc.xml · nonDerivative · entry 5 Garg Pushkal · CIK 0001829252 · CMO & EVP Dev & Med Affairs 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,929 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form. F6 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $ 195.50 to $196.09. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| April 27, 2023 Filed Apr 28, 2023 21:54 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 779 | $194.94 | $151,858.26 |
DisclosureSEC source: 0001735276-23-000044 · edgardoc.xml · nonDerivative · entry 4 Garg Pushkal · CIK 0001829252 · CMO & EVP Dev & Med Affairs 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,009 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form. F5 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $ 194.49 to $195.49. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| April 27, 2023 Filed Apr 28, 2023 21:54 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 700 | $193.93 | $135,751.00 |
DisclosureSEC source: 0001735276-23-000044 · edgardoc.xml · nonDerivative · entry 3 Garg Pushkal · CIK 0001829252 · CMO & EVP Dev & Med Affairs 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,788 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form. F4 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $ 193.48 to $194.48. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| April 27, 2023 Filed Apr 28, 2023 21:54 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 151 | $193.18 | $29,170.18 |
DisclosureSEC source: 0001735276-23-000044 · edgardoc.xml · nonDerivative · entry 2 Garg Pushkal · CIK 0001829252 · CMO & EVP Dev & Med Affairs 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,488 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form. F3 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $ 192.47 to $193.47. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| April 26, 2023 Filed Apr 28, 2023 21:54 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantCommon Stock | 4,294 | $0.00 | $0.00 |
DisclosureSEC source: 0001735276-23-000044 · edgardoc.xml · nonDerivative · entry 1 Garg Pushkal · CIK 0001829252 · CMO & EVP Dev & Med Affairs 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,639 F1 · kind: On February 23, 2022, the reporting person was granted performance-based stock units (PSUs) in connection with the issuer 2021 year-end compensation review. The PSUs vest in separate installments based on the achievement of three specified performance measures as determined by the People, Culture and Compensation Committee of the issuer Board of Directors. The shares reported were issued to the reporting person upon vesting of one-third of the PSUs based on achievement of a corresponding performance measure relating to the issuer public reporting of human proof-of-concept of an investigational therapeutic directed to an extrahepatic target (central nervous system, or CNS). Read SEC document |
| March 03, 2023 Filed Mar 7, 2023 21:07 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionStock Option (right to buy) · Derivative | 2,500 | $0.00 Strike: $96.45 | $0.00 |
DisclosureSEC source: 0001735276-23-000033 · edgardoc.xml · derivative · entry 7 Garg Pushkal · CIK 0001829252 · CMO & EVP Dev & Med Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,500 shares Expires 2024-12-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 16, 2022. F4 · derivative.exercise_date: The stock option vested as to 25% of the shares on the first anniversary of the grant date and as to an additional 6.25% of the shares at the end of each successive three month period thereafter until the fourth anniversary of the grant date, and were fully vested on December 17, 2018. Read SEC document |
| March 03, 2023 Filed Mar 7, 2023 21:07 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionPerformance Stock Option 2014 (right to buy) · Derivative | 2,500 | $0.00 Strike: $96.45 | $0.00 |
DisclosureSEC source: 0001735276-23-000033 · edgardoc.xml · derivative · entry 6 Garg Pushkal · CIK 0001829252 · CMO & EVP Dev & Med Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,500 shares Expires 2024-12-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 16, 2022. Read SEC document |
| March 03, 2023 Filed Mar 7, 2023 21:07 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 18,072 | $200.00 | $3,614,400.00 |
DisclosureSEC source: 0001735276-23-000033 · edgardoc.xml · nonDerivative · entry 3 Garg Pushkal · CIK 0001829252 · CMO & EVP Dev & Med Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,345 F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 16, 2022. Read SEC document |
| March 03, 2023 Filed Mar 7, 2023 21:07 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionCommon Stock | 2,500 | $96.45 | $241,125.00 |
DisclosureSEC source: 0001735276-23-000033 · edgardoc.xml · nonDerivative · entry 2 Garg Pushkal · CIK 0001829252 · CMO & EVP Dev & Med Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,417 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 16, 2022. Read SEC document |
| March 03, 2023 Filed Mar 7, 2023 21:07 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionCommon Stock | 2,500 | $96.45 | $241,125.00 |
DisclosureSEC source: 0001735276-23-000033 · edgardoc.xml · nonDerivative · entry 1 Garg Pushkal · CIK 0001829252 · CMO & EVP Dev & Med Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,917 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 16, 2022. Read SEC document |
| February 27, 2023 Filed Mar 1, 2023 21:22 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantStock Option (right to buy) · Derivative | 11,850 | $0.00 Strike: $190.01 | $0.00 |
DisclosureSEC source: 0001735276-23-000029 · edgardoc.xml · derivative · entry 2 Garg Pushkal · CIK 0001829252 · CMO & EVP Dev & Med Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,850 Underlying: Common Stock · 11,850 shares Expires 2033-02-27 F4 · shares: Represents the time-vested stock option portion of the reporting person's annual equity award granted in 2023 for 2022 performance. F5 · derivative.exercise_date: The stock option vests as to 25% of the shares on the first anniversary of the grant date and as to an additional 6.25% of the shares at the end of each successive three month period thereafter until the fourth anniversary of the grant date. Read SEC document |
| February 27, 2023 Filed Mar 1, 2023 21:22 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantRestricted Stock Units · Derivative | 5,724 | $0.00 | $0.00 |
DisclosureSEC source: 0001735276-23-000029 · edgardoc.xml · derivative · entry 1 Garg Pushkal · CIK 0001829252 · CMO & EVP Dev & Med Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,724 Underlying: Common Stock · 5,724 shares Expires 2026-02-27 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of ALNY common stock. F2 · shares: Represents the time-vested restricted stock unit portion of the reporting person's annual equity award granted in 2023 for 2022 performance. The reporting person also received 11,447 performance stock units as part of their annual equity award that will vest upon the achievement of three specific performance conditions (subject to a one year minimum vesting period), which will be reported on a Form 4 as to the performance stock units allocated to each performance condition if and when each performance condition is met and the performance stock units vest. F3 · derivative.exercise_date: The restricted stock units vest ratably in three installments, with one third vesting on each of the first, second and third anniversaries of the grant date. F3 · derivative.expiration_date: The restricted stock units vest ratably in three installments, with one third vesting on each of the first, second and third anniversaries of the grant date. Read SEC document |
| August 04, 2022 Filed Aug 5, 2022 20:14 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Tax withholdingCommon Stock | 146 | $210.02 | $30,662.92 |
DisclosureSEC source: 0001735276-22-000065 · edgardoc.xml · nonDerivative · entry 7 Garg Pushkal · CIK 0001829252 · CMO & EVP Dev & Med Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,417 F4 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting event. Read SEC document |
| August 04, 2022 Filed Aug 5, 2022 20:14 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Tax withholdingCommon Stock | 172 | $209.91 | $36,104.52 |
DisclosureSEC source: 0001735276-22-000065 · edgardoc.xml · nonDerivative · entry 6 Garg Pushkal · CIK 0001829252 · CMO & EVP Dev & Med Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,563 F4 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting event. Read SEC document |
| August 04, 2022 Filed Aug 5, 2022 20:14 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Tax withholdingCommon Stock | 165 | $205.87 | $33,968.55 |
DisclosureSEC source: 0001735276-22-000065 · edgardoc.xml · nonDerivative · entry 5 Garg Pushkal · CIK 0001829252 · CMO & EVP Dev & Med Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,735 F4 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting event. Read SEC document |
| August 04, 2022 Filed Aug 5, 2022 20:14 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Tax withholdingCommon Stock | 4,603 | $189.76 | $873,465.28 |
DisclosureSEC source: 0001735276-22-000065 · edgardoc.xml · nonDerivative · entry 4 Garg Pushkal · CIK 0001829252 · CMO & EVP Dev & Med Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,900 F4 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting event. Read SEC document |
| August 03, 2022 Filed Aug 5, 2022 20:14 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantCommon Stock | 3,109 | $0.00 | $0.00 |
DisclosureSEC source: 0001735276-22-000065 · edgardoc.xml · nonDerivative · entry 3 Garg Pushkal · CIK 0001829252 · CMO & EVP Dev & Med Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,503 F3 · kind: On February 24, 2021, the reporting person was granted performance-based stock units (PSU) in connection with the 2020 year-end compensation review. One quarter of the PSU award vests upon the achievement of each of four specific clinical development, regulatory or commercial events. The People, Culture and Compensation Committee of the Board determined that the first performance criterion was met and the first quarter of the PSU award vested as of August 3, 2022. Read SEC document |
| August 03, 2022 Filed Aug 5, 2022 20:14 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantCommon Stock | 3,684 | $0.00 | $0.00 |
DisclosureSEC source: 0001735276-22-000065 · edgardoc.xml · nonDerivative · entry 2 Garg Pushkal · CIK 0001829252 · CMO & EVP Dev & Med Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,394 F2 · kind: On October 7, 2020, the reporting person was granted a one-time strategic performance-based stock unit (PSU) award. The People, Culture and Compensation Committee of the Board determined that the performance criterion was met and the PSU award vested as of August 3, 2022. Read SEC document |
| August 03, 2022 Filed Aug 5, 2022 20:14 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantCommon Stock | 4,518 | $0.00 | $0.00 |
DisclosureSEC source: 0001735276-22-000065 · edgardoc.xml · nonDerivative · entry 1 Garg Pushkal · CIK 0001829252 · CMO & EVP Dev & Med Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,710 F1 · kind: On February 26, 2020, the reporting person was granted performance-based stock units (PSU) in connection with the 2019 year-end compensation review. One third of the PSU award vests upon the achievement of each of three specific clinical development, regulatory or commercial events. The People, Culture and Compensation Committee of the Board determined that the second performance criterion was met and the second one-third of the PSU award vested as of August 3, 2022. Read SEC document |
| June 15, 2022 Filed Jun 16, 2022 17:01 UTC | SQZ Biotechnologies Co SQZ · Entity 112267 | GrantStock Option · Derivative | 20,000 | $0.00 Strike: $3.23 | $0.00 |
DisclosureSEC source: 0001209191-22-037488 · doc4.xml · derivative · entry 1 Garg Pushkal · CIK 0001829252 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2032-06-14 F1 · derivative.exercise_date: The option vests and become exercisable on the earlier of (i) June 15, 2023 or (ii) the day immediately prior to the date of the next annual meeting of stockholders following the date of grant, in each case subject to the recipient's continued service on the Board at such time. Read SEC document |
| February 23, 2022 Filed Feb 25, 2022 21:12 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantStock Option (right to buy) · Derivative | 24,128 | $0.00 Strike: $147.47 | $0.00 |
DisclosureSEC source: 0001735276-22-000037 · edgardoc.xml · derivative · entry 1 Garg Pushkal · CIK 0001829252 · CMO & EVP Dev & Med Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,128 Underlying: Common Stock · 24,128 shares Expires 2032-02-22 F1 · shares: Represents the time-vested stock option portion of the reporting person's Annual Equity Award for 2021. The reporting person also received 12,884 performance stock units that will vest upon the achievement of three specific performance conditions, which will be reported on a Form 4 if and when each performance condition is met and the performance stock units vest. F2 · derivative.exercise_date: The stock option vests as to 25% of the shares on the 1st anniversary of the date of the stock option grant and as to an additional 6.25% of the shares each successive three month period thereafter. Read SEC document |
| June 15, 2021 Filed Jun 17, 2021 17:16 UTC | SQZ Biotechnologies Co SQZ · Entity 112267 | GrantStock Option · Derivative | 10,500 | $0.00 Strike: $13.57 | $0.00 |
DisclosureSEC source: 0001209191-21-041538 · doc4.xml · derivative · entry 1 Garg Pushkal · CIK 0001829252 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,500 Underlying: Common Stock · 10,500 shares Expires 2031-06-14 F1 · derivative.exercise_date: The option vests and becomes exercisable on the earlier of (i) June 15, 2022 or (ii) the day immediately prior to the date of the Issuer's next annual meeting of stockholders following the date of grant, in each case subject to the Reporting Person's continued service on the Board. Read SEC document |
| October 29, 2020 Filed Oct 30, 2020 18:35 UTC | SQZ Biotechnologies Co SQZ · Entity 112267 | GrantStock Option · Derivative | 7,055 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0000899243-20-029988 · doc4.xml · derivative · entry 1 Garg Pushkal · CIK 0001829252 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,055 Underlying: Common Stock · 7,055 shares Expires 2030-10-28 F1 · derivative.exercise_date: The option vests and becomes exercisable on October 29, 2021. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.